U.S. health regulators are warning consumers not to use more than two dozen varieties of over-the-counter eyedrops because of the risk of infections that could lead to blindness.
The Food and Drug Administration advisory applies to lubricating drops sold by six companies, including CVS Health, Target, Rite Aid and Cardinal Health. Consumers should stop using the products immediately and avoid purchasing any that remain on pharmacy and store shelves, the FDA said in a statement Friday.
The agency asked the companies to recall their products last week, because FDA inspectors found unsanitary conditions and bacteria at the facility producing the drops. The FDA did not disclose the location of the factory or when it was inspected.
No injuries related to the products had been reported at the time of the announcement, but the FDA encouraged doctors and patients to submit cases through the agency’s online reporting system.
Earlier this year, federal officials linked an outbreak of drug-resistant bacteria to eyedrops from two companies, EzriCare and Delsam Pharma. More than 80 people in the U.S. tested positive for eye infections from the rare bacterial strain, according to the most recent update from the Centers for Disease Control and Prevention.
After the products were recalled in February, health inspectors visited the manufacturing plant in India that made the eyedrops and uncovered problems with how they were made and tested, including inadequate sterility measures.
What's being called an unprecedented breakthrough in cancer treatment recently completed a small trial at New York City's Memorial Sloan Kettering in 14 rectal cancer patients. The experimental trial with the drug dostarlimab resulted in 100 percent remission in all candidates, precluding the need for chemotherapy or surgery. Cheddar News anchor Hena Doba dives into this hopeful story.
Join Cheddar News as we break down the top headlines this morning including updates on the Jan. 6 hears, the PGA suspension of 17 of the world's best golfers, and NASA's plans to study UFOs.
Rick Pauls, President & CEO OF DiaMedica Therapeutics, joins Cheddar Innovates to discuss a new ischemic stroke treatment option that expands the window for effective therapy for stroke patients.
John Bencich, CEO of Achieve Life Sciences, joins Cheddar Innovates to discuss a new plant-based compound that's being used to fight nicotine addiction.
On this episode of Cheddar Innovates: CEO of Achieve Life Sciences discusses a new plant-based compound that's being used to fight nicotine addiction; President & CEO OF DiaMedica Therapeutics explains a new ischemic stroke treatment option that expands the window for effective therapy for stroke patients; Cheddar gets a look at Curiosity Stream's 'Asteroid Rush.'
Catching you up on the stories you need to know this morning, mass shooting victims testify on Capitol Hill, the White House outlines its plan to vaccinate kids younger than five years old, and we break down how to protect yourself from monkeypox.
The pharmaceutical giant Moderna says its updated 'bivalent' booster shot provides a stronger immune response against the Omicron variant of COVID-19 specifically. This week, Moderna plans to submit preliminary data to U.S. health officials in the hopes that its new booster will be available later this summer. Dr. Sampson Davis, emergency medicine physician, joins Cheddar News to discuss.
NASA has announced that the first official full-color images will be beamed back to Earth from the James Webb Telescope on July 12. Gregory L. Robinson, the director of the James Webb Space Telescope Program in the NASA Science Mission Directorate, joined Cheddar News to discuss the anticipated image drop. “We expect to see the universe different," he said. "Webb will allow us to see much, much clearer and deeper into the universe."
On this episode of Cheddar Reveals, Professor Laurence Hurst, Director of The Milner Centre for Evolution, discusses the mystery of human evolution that's still baffling scientists: why are humans still evolving, and why has the process sped up? Neville Sanjana, faculty member at NY Genome and New York University, breaks down the latest innovations in CRISPR genetic engineering and its applications from 'designer babies' to curing genetic conditions and diseases; Cheddar gets a look at Curiosity Stream's 'The Butterfly Effect.'
Neville Sanjana, faculty member at NY Genome and New York University, joins Cheddar Reveals to break down the latest innovations in CRISPR genetic engineering and its applications from 'designer babies' to curing genetic conditions and diseases.
